Why the study?
Does low dose empagliflozin reduce negative cardiovascular outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention?
Does low dose empagliflozin reduce negative cardiovascular outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention?
Adding low dose empagliflozin to standard care in diabetic patients with ACS after PCI did not significantly reduce negative cardiovascular outcomes at 6 months.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in diabetic ACS patients post-PCI; leaves open efficacy in larger randomized trials.
The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.
No takes yet. Share an insight, caveat, or question.
Adel et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: